Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16-17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

Hematol Oncol Stem Cell Ther. 2020 Jun;13(2):61-65. doi: 10.1016/j.hemonc.2019.12.003. Epub 2020 Mar 12.

Abstract

Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.

Keywords: ATG; Grafalon; Haploidentical HSCT; Pediatrics; Sickle cell disease; Thymoglobulin.

Publication types

  • Congress
  • Historical Article

MeSH terms

  • Anemia, Sickle Cell / therapy*
  • Animals
  • Antilymphocyte Serum / pharmacology
  • Antilymphocyte Serum / therapeutic use*
  • Europe
  • Female
  • Germany
  • Hematopoietic Stem Cell Transplantation / methods*
  • History, 21st Century
  • Humans
  • Male
  • Transplantation Conditioning / methods*
  • Transplantation, Haploidentical / methods*

Substances

  • Antilymphocyte Serum